Caribou Biosciences (CRBU) Projected to Announce Earnings on Wednesday

Caribou Biosciences (NASDAQ:CRBU) is projected to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to post earnings of ($0.33) per share and revenue of $2.2790 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.07. The company had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.21 million. Caribou Biosciences had a negative return on equity of 84.17% and a negative net margin of 1,189.14%. On average, analysts expect Caribou Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Caribou Biosciences Stock Up 4.7%

CRBU opened at $1.57 on Wednesday. The stock’s fifty day moving average is $1.77 and its two-hundred day moving average is $1.83. The company has a market capitalization of $155.71 million, a P/E ratio of -1.11 and a beta of 2.38. Caribou Biosciences has a 52 week low of $1.38 and a 52 week high of $3.54.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Caribou Biosciences in a report on Friday, July 17th. HC Wainwright raised their price target on Caribou Biosciences from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.67.

Hedge Funds Weigh In On Caribou Biosciences

Institutional investors have recently bought and sold shares of the business. Creative Planning purchased a new stake in Caribou Biosciences during the second quarter worth $25,000. Hudson Bay Capital Management LP bought a new stake in Caribou Biosciences during the 2nd quarter valued at $30,000. Russell Investments Group Ltd. increased its holdings in shares of Caribou Biosciences by 80.0% in the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock valued at $39,000 after acquiring an additional 10,824 shares during the period. Invesco Ltd. increased its holdings in shares of Caribou Biosciences by 187.2% in the 4th quarter. Invesco Ltd. now owns 35,063 shares of the company’s stock valued at $56,000 after acquiring an additional 22,856 shares during the period. Finally, Man Group plc bought a new position in shares of Caribou Biosciences in the 4th quarter worth $58,000. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.